GIV/Girdin is a central hub for profibrogenic signalling networks during liver fibrosis

Inmaculada Lopez-Sanchez, Ying Dunkel, Yoon-Seok Roh, Yash Mittal, Samuele De Minicis, Andrea Muranyi, Shalini Singh, Kandavel Shanmugam, Nakon Aroonsakool, Fiona Murray, Samuel B Ho, Ekihiro Seki, David A Brenner, Pradipta Ghosh* (Corresponding Author)

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

78 Citations (Scopus)


Progressive liver fibrosis is characterized by the deposition of collagen by activated hepatic stellate cells (HSCs). Activation of HSCs is a multiple receptor-driven process in which profibrotic signals are enhanced and antifibrotic pathways are suppressed. Here we report the discovery of a signalling platform comprising G protein subunit, Gαi and GIV, its guanine exchange factor (GEF), which serves as a central hub within the fibrogenic signalling network initiated by diverse classes of receptors. GIV is expressed in the liver after fibrogenic injury and is required for HSC activation. Once expressed, GIV enhances the profibrotic (PI3K-Akt-FoxO1 and TGFβ-SMAD) and inhibits the antifibrotic (cAMP-PKA-pCREB) pathways to skew the signalling network in favour of fibrosis, all via activation of Gαi. We also provide evidence that GIV may serve as a biomarker for progression of fibrosis after liver injury and a therapeutic target for arresting and/or reversing HSC activation during liver fibrosis.

Original languageEnglish
Article number4451
Number of pages18
JournalNature Communications
Early online date21 Jul 2014
Publication statusPublished - 21 Jul 2014

Bibliographical note

We thank Marilyn Farquhar (UCSD) and Mikel Garcia-Marcos (Boston U) for their
helpful comments and critiques during the preparation of this manuscript, Katsumi Miyai (Pathology, UCSD) for generously giving us access to liver autopsy samples used in this work, Timo Meerloo for help with the preparation of semithin cryosections used to perform the immunofluorescence analysis and Robert Esteban (Ventana Inc.) for optimization of IHC staining of liver sections. This work was supported by NIH grants CA160911 and DK099226, CAMS (Burroughs Wellcome Fund) and CSDA (Doris Duke Charitable Foundation) Awards to P.G. I.L.-S. was supported by American Heart Association (AHA no. 14POST20050025); Y.M. was supported by the Sarah Rogers Fellowship (UCSD). D.A.B was supported by P42ES010337, S.B.H. by Veterans Affairs Research Service, E.S. by R01AA020172, R01DK085252 and P42ES010337, and F.M. by
NIH HL091061.


  • Cell signalling
  • Liver fibrosis
  • Pathogenesis


Dive into the research topics of 'GIV/Girdin is a central hub for profibrogenic signalling networks during liver fibrosis'. Together they form a unique fingerprint.

Cite this